Prostate cancer is a common malignancy that disproportionately affects African-American men. Environmental factors and variation in genes responsible for chemical and dietary carcinogen metabolism and DNA damage repair may modulate risk. Fourteen single nucleotide polymorphisms in NAT2 and four NER genes (ERCC1, XPF/ERCC4, XPG/ERCC5 and CSB/ERCC6) were genotyped in a case-control study of 254 African-American prostate cancer cases and 301 healthy controls from Washington, DC. Smoking status, BMI, age and genetic ancestry were included as covariates in the association analyses. We found that individuals homozygous for the XPG/ERCC5 À72C/T promoter polymorphism had a significant reduction in risk, for prostate cancer (OR ¼ 0.12; 95% CI ¼ 0.03-0.48). A haplotype trend regression test also revealed a protective effect for the haplotype bearing the T allele (P ¼ 0.003). In silica analyses suggest a functional implication for the promoter variant since it deletes a GCF transcriptional factor-binding site responsible for the downregulation of transcription. The protective effect of the promoter SNP on risk for prostate cancer was independent of smoking. In contrast, none of the SNPs typed for NAT2, ERCC1, ERCC4 and ERCC6 showed significant association with risk. Additional tests for genotype interactions were not significant. We note that there may be other factors, such as dietary exposures, which may modulate prostate cancer risk in combination with genetic variation within the NAT2 and NER genes. Our results, in combination with previous observations of LOH for ERCC5 in prostate tumors, provide further evidence for a role of XPG/ERCC5 in the etiology of prostate cancer.
Introduction
DNA repair ability and response to genotoxic exposures is variable within human populations. 1, 2 Since these pathways play an important role in cancer risk, common genetic polymorphisms, likely contribute to individual variability to cancer susceptibility. Prostate cancer in particular is the leading cause of cancer death among African-American men having the highest age-specific rate of prostate cancer in the world. 3 The etiology of prostate cancer is not well understood; however, studies examining genetics, diet and lifestyle are increasingly attracting attention.
Cigarette smoking and the consumption of 'well-done' red meat-environmental factors-increase exposure of aromatic amines and heterocyclic amines within the body-both of which are genotoxic chemicals. 4 However, before aromatic amines and heterocyclic amines can become carcinogenic, they must be metabolically activated, first, to its intermediate form by N-oxidation (CYP1A2) then to its final carcinogenic form by Nacetyltransferases 1 and 2 (NAT-1 and NAT-2). 4 Given their important function in carcinogen metabolism, NAT gene sequence polymorphisms may result in variability in enzyme stability and function. 4 The N-acetyltransferase 1 (NAT1) and N-acetyltransferase 2 (NAT2) genes consist of a single exon 870-base pairs long on chromosome 8p22 (a chromosomal region commonly shown to display LOH in human tumors). Both the N-acetyltransferase 1 and N-acetyltransferase 2 proteins perform the tasks of N-acetylation (typically deactivation) and O-acetylation (typically activation) of aromatic and heterocyclic amine carcinogens and both have been shown to be expressed in the prostate and are highly polymorphic in humans and vary in frequency by population. 5 Currently, the N-acetyltransferase 1 and N-acetyltransferase 2 genes are known to contain over 25 different alleles. 5 Single nucleotide polymorphisms (SNPs) in the NAT genes result in the three commonly recognized acetylation phenotypes-slow, intermediate and rapid. The variability and functional impact of many of the N-acetyltransferase 2 polymorphisms have been studied across several cancers. [6] [7] [8] [9] [10] One of the most important and versatile DNA repair pathways is the (NER) pathway. This 'housekeeping' mechanism is the most complex repair process-requiring the participation of approximately 30-40 genes and is responsible for repairing many different forms of DNA damage such as crosslinks, UV-induced photoproducts, oxidative damage and bulky monoadducts.
1,2,11 NER repairs DNA damage caused by carcinogens such as tobacco-related polycyclic aromatic hydrocarbons and heterocyclic aromatic amines (HAAs) produced from 'well-done' meats and pesticides. 1, 12 The NER process includes a number of genes that are responsible for damage recognition, assembly of repair factors, DNA uncoiling (ERCC2/XPD and ERCC3/XPB), incision (ERCC1-ERCC4/XPF and ERCC5/XPG), excision, elongation and ligation. Excision and repair take place in one of two forms: global genome repair and transcription-coupled repair (TCR)-which includes, among additional proteins, ERCC6/CSB.
2,12-14 Polymorphisms in NER genes could contribute to impaired nucleotide excision repair capacity and possibly cancer risk.
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The functional importance of the NAT and NER genes in the prevention of carcinogenesis has been shown by the association of polymorphisms within these genes with many cancers. The NAT-2 gene has been associated with bladder cancer, 8, 15 cholangiocarcinoma, 16 and colorectal adenoma. 17 NER gene polymorphisms and deficient nucleotide excision repair capacity have been implicated in breast cancer, 12 basal cell carcinoma, 1 non-small-cell lung cancer, 1 bladder cancer, 18 colorectal adenoma 14 and cutaneous malignant melanoma.
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Given the role of NAT2 in the activation and deactivation of carcinogens that can create DNA adducts and NER genes in the repair of DNA adducts caused by carcinogens and their processing of the common genotoxic chemical (HAA), we examined polymorphisms in NAT2, and four NER genes (ERCC1, XPF/ERCC4, XPG/ ERCC5 and CSB/ERCC6) for the effects on the risk for prostate cancer in African Americans. Like many candidate genes for prostate cancer, many of the allele frequencies in NAT2 and NER pathway genes vary significantly across ethnicity. However, little is known about allele frequencies and their contribution to risk for prostate cancer for African Americans. Here, we examined 14 SNPs in 254 African-American prostate cancer cases and 301 healthy controls from Washington, DC. We performed structured association analyses to control for admixture stratification due to ethnic differences in allele frequencies. A protective effect against prostate cancer risk was observed for a 5 0 UTR variant in the XPG/ERCC5 gene in African Americans.
Materials and methods

Study subjects
Unrelated men (n ¼ 555) self-described as African Americans were recruited between the years 2001 and 2004 from the Division of Urology at Howard University Hospital in Washington, DC. Incident sporadic prostate cancer cases (n ¼ 254) with no family history were identified by a urologist within the division or study coordinator and confirmed by a review of medical records. Each prostate cancer patient was defined as not having one or more first-degree relatives and/or two or more second-degree relatives diagnosed with prostate cancer based on an extensive family history questionnaire. Healthy control subjects (n ¼ 301) unrelated to the cases and matched for age ( ± 5 years) were also ascertained from the Division of Urology at Howard University Hospital. Individuals who were ever diagnosed with benign prostate hyperplasia and/or had a prostate-specific antigen (PSA) value 42.5 ng ml À1 were not included as controls. All participants were between 40 and 85 years of age.
Information on smoking history was also collected at the time of recruitment using a short questionnaire. Men were classified as never smokers if they reported never smoking or smoking less than 100 cigarettes over their lifetime. Men, who responded as smokers, were asked how many cigarettes on average a day they smoked. Ever smokers were further classified as either smoking p14 or 415 cigarettes a day.
Blood samples for DNA extraction and PSA tests were collected for all participants. Clinical characteristics including Gleason grade, PSA, tumor-node-metastasis stage, age at diagnosis and family history were obtained for all cases from medical records (see Table 1 ). Disease aggressiveness was defined as 'low' (T category oT2c and/or Gleason grade o7) or 'high' (T category XT2c and/or Gleason grade X7). The Howard University IRB approved the study and written consent was obtained from all participants. Table 2 ) were selected and genotyped using MALDI-TOF Mass Spectrometry analysis (Sequenom Inc., San Diego, CA, USA). Genotyping assays were designed using the Sequenom MassARRAY Assay Design software and Homogeneous MassExtend (hME) chemistry. Polymerase chain reaction was performed using 2.5 ng ul À1 of genomic DNA, 0.25 U of Taq polymerase (Amplitaq Gold, Applied Biosystems, Foster City, CA, USA), 500 mmol of each dNTP and 100 nmol of each PCR primer. PCR thermal cycling was carried out in an ABI-9700 instrument for 15 min at 95 1C, followed by 45 cycles of 20 s at 95 1C, 30 s at 62 1C, 1 min at 72 1C and a final elongation of 3 min at 72 1C. Next, the SAP reaction was performed on the completed PCR by adding 2 ml of SAP enzyme solution (containing 0.3 U of Shrimp Alkaline Phosphatase) and incubation at 37 1C for 20 min followed by inactivation for 5 min at 85 1C. Unextended primer concentrations were then adjusted in an attempt to increase signal heights and the hME reaction cocktail was added to the post-SAP PCR. The hME reaction was then performed at 94 1C for 2 min, followed by 99 cycles of 5 s at 94 1C, 5 s at 52 1C and 5 s at 72 1C. The hME reaction products were then desalted by diluting samples with 16 ml of water, adding 6 mg of resin, mixing the resulting solution and then centrifuging to separate the hME reaction products from the resin. Finally, the products were spotted on a SpectroChip (Sequenom Inc.), processed and analyzed in the MassARRAY Typer Autoflex by MassARRAY software.
To control for possible confounding by population admixture, a panel of 34 ancestry informative markers (AIMs) was also genotyped for all the samples. These markers show large allele frequency differences (delta, d) between the ancestral populations for African Americans (West Africans and Europeans), and were used to control for the presence of population stratification (PS) due to admixture. [19] [20] [21] The description of this marker set has been provided in previous papers. 19, 22 AIM frequencies for West African (Central African Republic, Nigeria and Sierra Leone, N ¼ 480), and European (Spain, Germany, England and Ireland, N ¼ 243) populations were included in the analysis as representative of ancestral groups. Information regarding primer sequences, polymorphic sites and other relevant information on the AIMs are available upon request. Genotyping reproducibility was 499% for replicate-blinded samples.
Statistical analysis
Odds ratios (ORs), 95% confidence intervals and P-values were determined by logistic regression analyses from comparison of genotypes between individuals with prostate cancer and healthy controls using SPSS version 11. In addition, we calculated ORs which were adjusted for the following potential confounding variables and effect modifiers: age in years (at time of diagnosis for case subjects and at time of ascertainment for controls), smoking status (coded as 0 ¼ never smoked, 1 ¼ smokes 1-14 cigarettes a day, or 2 ¼ smokes 15 or more cigarettes a day) and individual ancestry (0-100% West African ancestry). Individual ancestry (IA) estimates were obtained using the panel of 34 ancestry informative markers (AIMs) typed in all subjects. Individual genetic ancestry (percentage of West African ancestry) was estimated from the AIM genotype data using the Bayesian Markov Chain Monte Carlo (MCMC) method implemented in the program STRUCTURE 2.1.
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STRUCTURE 2.1 was run under the admixture model using prior population information and independent allele frequencies. We ran the MCMC method using K ¼ 2 parental populations and a burn-in length of 30 000 for 70 000 repetitions.
An expectation maximization algorithm as implemented in SAS Genetics (SAS Institute Inc., Cary, NC, USA) was utilized to measure associations (R 2 ) between pairs 
Results
We examined a study population of 555 AfricanAmerican subjects (254 cases and 301 controls). Table 1 details that there were no significant differences between cases and controls for age, ever smoked tobacco and BMI. Significant differences between prostate cancer cases and controls were observed for PSA levels (P ¼ 0.001). For frequency of tobacco use, significantly more cases (56.6%) than controls (34.7%) smoked 415 cigarettes per day (P ¼ 0.02). Individual ancestry estimates based on 34 AIMs revealed similar levels of West African genetic ancestry among the cases and controls (81.1 versus 79.5%, respectively; P ¼ 0.49).
The allele and genotype frequencies of all selected SNPs among the controls were in agreement with the Hardy-Weinberg equilibrium expectations (P40.05). Table 2 shows the polymorphisms, genetic positions and allele frequencies of the 14 SNPs among our AfricanAmerican controls along with HAPMAP frequencies from west African (Nigeria), Chinese (Taiwan) and European (CEPH) descent samples. The allele frequency for many of the SNPs varied considerably between the West African and European HAPMAP samples (Table 2) .
SNP genotype frequencies for the NAT2 and NER genes and the unadjusted and adjusted odds ratios for association with prostate cancer are depicted in Tables 3   and 4 . Significant association with prostate cancer risk was observed for only 1 of the 14 SNPs. SNP rs2296148 within the ERCC5 gene was significantly associated with prostate cancer risk (P ¼ 0.003). We found that individuals homozygous for the ERCC5/XPG gene promoter polymorphism À72 T allele had a significant reduction in risk for prostate cancer (OR ¼ 0.12; 95%CI ¼ 0.03-0.48). Given that multiple association tests were performed, our a for the genotype association tests was set at 0.004 ( ¼ 0.05/14 independent genotype tests). Thus, the association of the rs2296148 SNP with prostate cancer was significant even after taking into account multiple testing. In contrast, none of the SNPs typed for the NAT2, ERCC1, ERCC4 and ERCC6 genes showed significant association with risk. Additionally, tests for genotype interactions were not significant (data not shown).
Since each of the five genes are on different chromosomes, we examined marker associations for both linked and unlinked SNPs. Figure 1 depicts the pairwise associations (R 2 ) of NAT2 and NER gene SNPs. Overall, there was very low association of unlinked SNPs that would suggest that there is little evidence for population stratification in the sample set. As shown in the boxed segments of Figure 1 , the linked SNPs within the four genes exhibit mild to strong, yet significant, R 2 values. The low correlation between these particular unlinked SNPs in the cases and controls also support the lack of genetic interaction between these selected SNPs on prostate cancer risk.
Risk for prostate cancer was further evaluated by haplotype analyses using multilocus SNPs within the NAT2, ERCC6, ERCC5 and ERCC4 genes. Haplotype analysis provided similar results to the single SNP associations. ERCC5 haplotypes constructed using SNPs rs2296148 and rs4150313 were tested for association with prostate cancer. The haplotype trend regression test revealed a significant effect on disease risk (OR ¼ 0.41; 
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However, this finding did not meet the significance test after correcting for multiple testing (P ¼ 0.03).
Since the ERCC5 C/T SNP was within the 5 0 UTR we performed an in silica analysis using the Tfsitescan website (http://www.ifti.org) to determine if the T allele alters any potential transcriptional factor binding sites. Interestingly, the T allele putatively deletes both a SP-1 and a GCF transcription binding site near position À72. Obviously, this may have potential functional significance given that GCF is a potent downregulator of gene expression. The loss of the GCF site may lead to an increase in ERCC5 expression among TT homozygotes compared to the wild-type genotype.
Discussion
The NAT and NER genes play a role in the metabolism and effects of carcinogens in the body. It has been shown that aromatic amines can cause DNA damage and produce DNA adducts in human prostate epithelial cells in vitro. 25 Also human prostate epithelial cells express NATs and are capable of activating heterocyclic amines. 26 In addition, the NER genes, ERCC1, 3, 5, 6 and XPC genes are expressed in the prostate 11 and prostate cells have also been shown to possess the ability to activate both polycyclic aromatic hydrocarbons and heterocyclic aromatic amines. 2 While several studies have examined NAT genes and prostate cancer risk, there is a lack of consensus on their role and impact on the disease, 9, 26, 27 which is likely because of variability in environmental exposures and allele frequencies across populations. Studies concerning NER genes and prostate cancer risk have been performed mainly in European descent populations with varying results. 1, 2, 28, 29 However, few studies have focused on NER gene variation and prostate cancer risk in a large number of African Americans.
Our study is the first to look for a possible relationship between polymorphisms in the NAT-2 and NER genes and prostate cancer risk in an African-American population. African Americans are twice as likely to develop prostate cancer than European Americans. 30 We found that a common C/T SNP in the 5 0 UTR of ERCC5 significantly influenced risk for prostate cancer (P ¼ 0.003). Individuals with the TT genotype were eight times less likely to develop prostate cancer compared to the CC genotype (Table 4) . Interestingly, this variant is found in much lower frequency among European and Asian descent populations compared to African Americans (Table 2) . We caution, however, that although there appears to be a protective effect with rs2296148; this result should be regarded as preliminary until it is replicated in a larger population.
Our data revealed no significant association for the other 13 NAT2, ERCC1, XPF/ERCC4 and CSB/ERCC6 polymorphisms-individually or in combination-with prostate cancer. Although we observed no relationship between these genotypes and prostate cancer risk, we cannot rule these genes out as potential risk factors since many genes are involved in the N-acetyltransferase and 
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S Hooker et al nucleotide excision repair pathways. Given our strict criteria for SNP ascertainment using dbSNP and HAP-MAP databases, we were only able to capture a small percentage of the total genetic variation in the candidate genes we studied. An assessment of a much larger set of SNPs (such as tagger SNPS) within NAT2 and NER genes is needed to capture the bulk of genetic variability for these genes. It is likely that these variants and/or others we did not study, have additive or multiplicative effects on prostate cancer risk. Our assessment of the functional significance of the ERCC5 C-72T polymorphism using computational modeling suggest that the rs2296148 T allele alters a GCF transcription factor-binding site in the 5 0 regulatory region of ERCC5. GCF transcription factor is known to be involved in the downregulation of gene transcription. 31 We suggest that possession of the T allele leads to the deletion of this GCF site and subsequently, an increase in the production of the XPG protein. The XP group G (XPG, also called ERCC5 or the excision repair cross-complementing group 5) gene encodes a DNA endonuclease that participates in the process of excision repair by removing the damaged DNA sequence. 2 We note that the XPG gene is mapped to a region on 13q33, which has shown frequent loss of heterozygosity in human prostate cancer. 32 The increase in the amount of XPG protein may potentially affect the efficiency of the NER process. However, further functional work is needed to confirm this hypothesis.
Besides NER, the XPG protein also participates in base excision repair (BER), albeit bearing a different function. BER is the major repair pathway for removal of thymine glycol (Tg) lesions. 33 BER corrects base damage, which occurs endogenously by hydrolysis or exposure to active oxygen by excising the altered base.
NER genes are highly expressed in proliferating tissues such as the prostate, possibly due to their greater need for repair and proofreading of newly replicated DNA. 11 Genetic polymorphisms in these repair genes may impact DNA repair capacity and prostate carcinogenesis. We note that in addition to unstudied polymorphisms, there may be other factors, such as dietary exposures, which may modulate prostate cancer risk in combination with genetic variation within the NAT2 and NER genes. A large population-based study is warranted to study the impact of these exposures through the life course of men with and without the disease.
